TY - JOUR
T1 - Anxiolytic-like effects of alverine citrate in experimental mouse models of anxiety
AU - Gupta, Deepali
AU - Radhakrishnan, Mahesh
AU - Kurhe, Yeshwant
N1 - Publisher Copyright:
© 2014 Elsevier B.V.
PY - 2014
Y1 - 2014
N2 - Anxiety disorders are widely spread psychiatric illnesses that are a cause of major concern. Despite a consistent increase in anxiolytics, the prevalence of anxiety is static; this necessitates the development of new compounds with potential activity and minimum unwanted effects. A serotonergic (5HT) system plays an important role in pathogenesis of anxiety and predominantly involves 5HT1Areceptor action in mediating anxiety-like behavior; the antagonism of 5HT1Areceptor has demonstrated to produce anxiolytic-like effects. Alverine citrate (AVC) is reported as a 5HT1Aantagonist; however, its effects on anxiety-like behavior are not investigated. Thus, the present study, by utilizing a neurobehavioral approach, examined the anxiolytic-like effects of AVC in experimental mouse models of anxiety. Mice were acutely treated with AVC (5–20 mg/kg, i.p.)/diazepam (DIA, 2 mg/kg, i.p.) and subjected to four validated anxiety models viz. elevated plus-maze (EPM), light/dark (L/D), hole-board (HB) and marble burying (MB) tests. AVC (15–20 mg/kg) and DIA significantly increased open arm activity in EPM, exploration in light chamber in L/D test, exploratory behavior in HB and reduced MB behavior in marble burying test. AVC (5 mg/kg) had no effect on all behavioral tests, while AVC (10 mg/kg) produced partial effects. It revealed anxiolytic-like effects of AVC. Furthermore, anxiolytic-like effects of AVC at higher doses (15–20 mg/kg) were more pronounced than lower doses (10 mg/kg) and were quite similar to the standard drug DIA. The present finding demonstrates, for the first time, the anxiolytic-like effects of AVC, which may be an alternative approach for management of anxiety-related disorders.
AB - Anxiety disorders are widely spread psychiatric illnesses that are a cause of major concern. Despite a consistent increase in anxiolytics, the prevalence of anxiety is static; this necessitates the development of new compounds with potential activity and minimum unwanted effects. A serotonergic (5HT) system plays an important role in pathogenesis of anxiety and predominantly involves 5HT1Areceptor action in mediating anxiety-like behavior; the antagonism of 5HT1Areceptor has demonstrated to produce anxiolytic-like effects. Alverine citrate (AVC) is reported as a 5HT1Aantagonist; however, its effects on anxiety-like behavior are not investigated. Thus, the present study, by utilizing a neurobehavioral approach, examined the anxiolytic-like effects of AVC in experimental mouse models of anxiety. Mice were acutely treated with AVC (5–20 mg/kg, i.p.)/diazepam (DIA, 2 mg/kg, i.p.) and subjected to four validated anxiety models viz. elevated plus-maze (EPM), light/dark (L/D), hole-board (HB) and marble burying (MB) tests. AVC (15–20 mg/kg) and DIA significantly increased open arm activity in EPM, exploration in light chamber in L/D test, exploratory behavior in HB and reduced MB behavior in marble burying test. AVC (5 mg/kg) had no effect on all behavioral tests, while AVC (10 mg/kg) produced partial effects. It revealed anxiolytic-like effects of AVC. Furthermore, anxiolytic-like effects of AVC at higher doses (15–20 mg/kg) were more pronounced than lower doses (10 mg/kg) and were quite similar to the standard drug DIA. The present finding demonstrates, for the first time, the anxiolytic-like effects of AVC, which may be an alternative approach for management of anxiety-related disorders.
KW - 5HTantagonist
KW - Alverine citrate
KW - Anxiolytic-like effects
KW - Elevated-plus maze
KW - Hole-board
KW - Marble burying test
UR - http://www.scopus.com/inward/record.url?scp=84940024345&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940024345&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2014.08.033
DO - 10.1016/j.ejphar.2014.08.033
M3 - Article
C2 - 25199966
AN - SCOPUS:84940024345
SN - 0014-2999
VL - 742
SP - 94
EP - 101
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
ER -